Back Hepatitis C

Hepatitis C

AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study

An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response in 85% of Japanese patients with hepatitis C virus subtype 1b, according to findings presented at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%

Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.

alt

AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks

A combination of 3 direct-acting antivirals developed by Bristol-Myers Squibb --daclatasvir, asunaprevir, and BMS-791325 -- cured chronic hepatitis C virus (HCV) infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson from the University of Colorado reported this week at the 64thAASLD Liver Meeting in Washington, DC. The combination proved equally effective in people with genotype 1a and 1b HCV.

alt

AASLD 2013: Viral Hepatitis Is a Leading Cause of Death Worldwide

The 2010 Global Burden of Disease Study -- the first to include underlying causes of deaths due to cirrhosis and liver cancer -- has identified chronic viral hepatitis as one of the leading causes of mortality worldwide, according to a presentation this week at the 64th AASLD Liver Meeting in Washington, DC. About 45% of liver cancer and 30% of cirrhosis is related to chronic hepatitis B, which is endemic in much of Asia and Africa, while chronic hepatitis C and alcohol use are each responsible for about 25% of deaths.

alt

AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%

A 2-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virological response (SVR) in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need for pegylated interferon or ribavirin, Eric Lawitz from the Texas Liver Institute reported Sunday at the 64th AASLD Liver Meeting in Washington, DC. In people who had failed to respond to a previous course of pegylated interferon and ribavirin, the same combination achieved SVR in 90%.

alt

AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence

An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those treated after transplantation, according to studies presented this week at the 64thAASLD Liver Meeting in Washington, DC.

alt

AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women

Two large studies of the "Baby Boom" generation in the U.S. suggest that at least 50,000 military veterans may have undiagnosed hepatitis C, and that around 80% of patients born between 1945 and 1965 receiving care through 4 large primary health care systems could be undiagnosed, according to presentations at the 64th AASLD Liver Meeting in Washington DC. Other research showed that screening pregnant women for hepatitis C on the basis of self-disclosed risk factors would have missed almost three-quarters infections in this population between 2003 and 2010.

alt

AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study

A 2-drug combination of direct-acting antivirals developed by Merck, MK-5172 and MK-8742, with or without ribavirin, achieved very high cure rates in patients with genotype 1 hepatitis C in a small study presented this week at the 64th AASLD Liver Meeting in Washington, DC.

alt

AASLD 2013: Liver Meeting Opens with a Focus on Hepatitis C

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting kicked off Saturday, November 2, with an overview for the media by AASLD president Gregory Fitz. With the first next-generation direct-acting antivirals (DAAs) poised to emerge from the pipeline, hepatitis C and its treatment have generated the most interest and excitement at the conference.

alt